stockrowTakeda Pharmaceutical Co.
TAK Healthcare Drug Manufacturers Specialty & Generic
Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025.
- Revenue
- +1.71%
- EPS
- −4.35%
- Free cash flow
- +54.9%
- Total debt
- −7.28%
Quarter to September 2026, against a year earlier
Follow TAK
Alert me
Takeda Pharmaceutical Co. (TAK) Price to free cash flow
As of 5 November 2026, Takeda Pharmaceutical Co. (TAK) trades at a price to free cash flow of 8.4×. Over the past ten years it has ranged from 0.0× (March 2024) to 44.8× (October 2023); the current reading is higher than 73% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 16.3× and below the Healthcare sector median of 21.1×.
Price to free cash flow, daily
Embed this chart
Annual newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| FY2026 | 5.3× | (22.43%) |
| FY2025 | 6.9× | (72.94%) |
| FY2024 | 25.4× | 26.48% |
| FY2023 | 20.1× | 274.48% |
| FY2022 | 5.4× | (27.51%) |
| FY2021 | 7.4× | (33.16%) |
| FY2020 | 11.1× | 142.03% |
| FY2019 | 4.6× | 14.46% |
| FY2018 | 4.0× | 0.20% |
| FY2017 | 4.0× | 3.17% |
Quarterly newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| Jun 2026 | 6.8× | (10.77%) |
| Jun 2025 | 7.6× | (40.29%) |
| Jun 2024 | 12.8× | (49.53%) |
| Mar 2024 | 25.4× | — |
| 25 more quarters | Free account |
Against its own ten years
Price to free cash flow against peers
| Company | Price to free cash flow |
|---|---|
| TAK Takeda Pharmaceutical Co. | 8.4× |
| HLN Haleon PLC Sponsored ADR compare | 9.2× |
| VTRS Viatris Inc. compare | 10.7× |
| ZTS Zoetis Inc. compare | 14.7× |
| NBIX Neurocrine Biosciences, Inc. compare | 15.7× |
| UTHR United Therapeutics Corporation compare | 28.0× |
| ELAN Elanco Animal Health Incorporated compare | 33.2× |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 36.6× |
| RDY Dr. Reddy's Laboratories Ltd compare | 126× |
| Drug Manufacturers Specialty & Generic industry median | 16.3× |
| Healthcare sector median | 21.1× |
| Market median | 14.1× |
What Price to free cash flow is
Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.
Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))
More on TAK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement